scholarly article | Q13442814 |
P356 | DOI | 10.1080/08039488.2016.1230649 |
P698 | PubMed publication ID | 27658459 |
P50 | author | Olli Kampman | Q40680939 |
Mari Hämäläinen | Q42291296 | ||
Esa Leinonen | Q114130753 | ||
Merja L Viikki | Q114130758 | ||
Niko Seppälä | Q114130791 | ||
P2093 | author name string | Eeva Moilanen | |
Jari-Pekka Klemettilä | |||
P2860 | cites work | A Systematic Review of Mortality in Schizophrenia | Q22253025 |
Human resistin in cardiovascular disease | Q27025765 | ||
Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects | Q28657600 | ||
Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways | Q33762512 | ||
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). | Q34018491 | ||
Adipose tissue, inflammation and atherosclerosis | Q34096337 | ||
Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes | Q34765830 | ||
Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study | Q34944648 | ||
Adipokine resistin predicts anti-inflammatory effect of glucocorticoids in asthma | Q35052648 | ||
Association of circulating resistin with metabolic risk factors in Indian females having metabolic syndrome | Q35245193 | ||
Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia | Q35369617 | ||
Factors associated with inflammation markers, a cross-sectional analysis | Q35633792 | ||
Sexual differences in the control of energy homeostasis | Q35896671 | ||
Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics | Q36301864 | ||
Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis | Q36621075 | ||
The cytokine network in asthma and chronic obstructive pulmonary disease | Q36955575 | ||
Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts | Q37067145 | ||
Resistin, adiponectin, and risk of heart failure the Framingham offspring study | Q37178491 | ||
Effects of tobacco smoke on immunity, inflammation and autoimmunity | Q37665006 | ||
COPD and the metabolic syndrome: an intriguing association. | Q37941499 | ||
The adipocyte as an endocrine organ in the regulation of metabolic homeostasis | Q37971439 | ||
Functional and structural features of adipokine family | Q38047622 | ||
Dietary pattern analysis and biomarkers of low-grade inflammation: a systematic literature review | Q38122431 | ||
Adipokines as drug targets in joint and bone disease. | Q38125858 | ||
The social and economic burden of treatment-resistant schizophrenia: a systematic literature review | Q38133371 | ||
Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis | Q38398066 | ||
Mortality and causes of death in schizophrenia in Stockholm county, Sweden | Q38495726 | ||
Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis. | Q38545272 | ||
Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia | Q41734144 | ||
Plasma resistin levels are associated with insulin resistance in older Japanese men from a rural village | Q44537213 | ||
Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine | Q45372399 | ||
Adipocytokine resistin correlates with oxidative stress and myocardial injury in patients undergoing cardiac surgery | Q45817748 | ||
Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. | Q45906631 | ||
Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics | Q46416824 | ||
Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia | Q46564715 | ||
Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis. | Q46568292 | ||
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment | Q46595376 | ||
Smoking and weight among patients using clozapine | Q47173896 | ||
The expression of human resistin in different leucocyte lineages is modulated by LPS and TNFalpha | Q47790914 | ||
Association study of the HTR2C, leptin and adiponectin genes and serum marker analyses in clozapine treated long-term patients with schizophrenia. | Q50619277 | ||
Smoking associates with visceral fat accumulation especially in women. | Q50711325 | ||
Resistin is linked to inflammation, and leptin to metabolic syndrome, in women with inflammatory arthritis. | Q51483437 | ||
The association of resistin with coronary disease in the general population. | Q54647001 | ||
Resistin Is an Indicator of the Metabolic Syndrome According to Five Different Definitions in the Finnish Health 2000 Survey | Q57417417 | ||
P433 | issue | 2 | |
P921 | main subject | schizophrenia | Q41112 |
P304 | page(s) | 89-95 | |
P577 | publication date | 2016-09-23 | |
P1433 | published in | Nordic Journal of Psychiatry | Q15751569 |
P1476 | title | Resistin as an inflammatory marker in patients with schizophrenia treated with clozapine | |
P478 | volume | 71 |
Q58712660 | C-Reactive Protein as a Peripheral Biomarker in Schizophrenia. An Updated Systematic Review |
Q47612632 | C-reactive protein levels and treatment resistance in schizophrenia-A Danish population-based cohort study |
Q94561344 | Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics |
Q90365072 | Monocyte count in schizophrenia and related disorders: a systematic review and meta-analysis |
Search more.